Loading clinical trials...

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

A Phase I Study of Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

NCT01579994•Memorial Sloan Kettering Cancer Center

Summary

About 18 patients will take part in the phase 1 portion of the trial. In the beginning of the study, 3 patients will be treated with a low dose of ganetespib (STA-9090) and the standard dose of crizotinib. If this dose does not cause significant side effects, it will be increased as new patients take part in the study. The study will only be open at Memorial Sloan Kettering Cancer Center.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically or cytologically proven diagnosis confirmed at MSKCC of advanced lung adenocarcinoma that is locally advanced or metastatic (stage III/IV).
•Positive for translocation or inversion events involving the ALK gene locus as determined standard methods (including but not limited to by FISH and IHC testing).
•No prior treatment with crizotinib, but they may have received prior cytotoxic chemotherapy.
•Age ≥ 18 years.
•Measurable (RECIST 1.1) indicator lesion not previously irradiated.
•Karnofsky Performance Status ≥ 70%
•Able to take oral medications
•A negative serum pregnancy test obtained within two weeks prior to administration of the experimental agents in all pre-menopausal women (last menstrual period ≤ 24 months ago).
•All women of child bearing potential (WOCBP) and sexually active men must agree to use adequate methods of birth control throughout the study which include use of oral contraceptives with an additional barrier method, double barrier methods (diaphragm with spermicidal gel or condoms with contraceptive foam), Depo-Provera, partner vasectomy and/or tubal libation and total abstinence.

Exclusion Criteria

•Prior crizotinib therapy
•Inadequate recovery from any toxicity related to prior treatment (to Grade 1 or baseline).
•Inadequate hematologic function defined as:
•* Absolute neutrophil count (ANC) \< 1,000 cells/mm³.
•* Platelet count \< 75,000/mm³
•* Hemoglobin \< 9.0g/dL.
•Inadequate hepatic function defined by:
•AST and/or ALT \> 3x upper limited of normal (ULN).
•Total bilirubin \> 2x ULN.
•Alkaline phosphatase \> 3x ULN.
+10 more criteria

Locations (5)

Memoral Sloan Kettering Cancer Center

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Cancer Center @ Suffolk

Commack, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Memorial Sloan Kettering at Mercy Medical Center

Rockville Centre, New York, United States

Memoral Sloan Kettering Cancer Center at Phelps

Sleepy Hollow, New York, United States

Key Dates

Start Date

April 16, 2012

Primary Completion Date

December 28, 2020

Completion Date

December 28, 2020

Last Updated

December 30, 2020

Enrollment

ACTUAL participants

Conditions

Advanced Lung Cancer

Interventions

Ganetespib (STA-9090) and crizotinib

DRUG

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775

Solid Tumor, AdultMetastatic Breast Cancer+9 more

View study

RECRUITINGPHASE1

Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer

NCT06945523

Advanced Lung Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 30, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

Inclusion Criteria

Exclusion Criteria

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer

A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL)